NCT00519532 - Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Parkinson's Disease

Interventions

DRUG

Rotigotine

"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"

Trial Locations (21)

1145

Budapest

4400

Nyíregyháza

10713

Berlin

20127

Milan

28144

Salisbury

33701

St. Petersburg

34128

Kassel

35039

Marburg

89081

Ulm

90220

Oulu

Unknown

Concord

Chieti

Christchurch

Olyszytn

Cape Town

Barcelona

Madrid

Lancashire

01307

Dresden

06618

Naumburg

L9 7JL

Liverpool